Combenefit: An interactive platform for the analysis and visualisation of drug combinations by di, Veroli Giovanni Y et al.
 Systems biology 
Combenefit: An interactive platform for the 
analysis and visualisation of drug combina-
tions 
 
Giovanni Y. Di Veroli
1,2*
, Chiara Fornari
1
, Dennis Wang
3
, Séverine Mollard
1
, Jo L. 
Bramhall
1
, Frances M. Richards
1
, and Duncan I. Jodrell
1
 
1
CRUK Cambridge Institute, University of Cambridge, UK 
2
Early Clinical Development, Innovative Medicines and 
Early Development Biotech Unit, AstraZeneca-Cambridge 
3
Bioinformatics, Oncology Innovative Medicines, Astra-
Zeneca, UK *To whom correspondence should be addressed. 
Abstract 
Motivation: Many drug combinations are routinely assessed to identify synergistic interactions in the 
attempt to develop novel treatment strategies. Appropriate software is required to analyse the results 
of these studies. 
Results: We present Combenefit, new free software tool that enables the visualisation, analysis and 
quantification of drug combination effects in terms of synergy and/or antagonism. Data from combina-
tions assays can be processed using classical Synergy models (Loewe, Bliss, HSA), as single exper-
iments or in batch for High Throughput Screens. This user-friendly tool provides laboratory scientists 
with an easy and systematic way to analyse their data. The companion package provides bioinfor-
maticians with critical implementations of routines enabling the processing of combination data. 
Availability and Implementation: Combenefit is provided as a Matlab package but also as 
standalone software for Windows (http://sourceforge.net/projects/combenefit/).  
Contact: Giovanni.DiVeroli@cruk.cam.ac.uk 
Supplementary Information: Supplementary data are available at Bioinformatics online. 
 
 
1 Introduction  
The combination of drugs is an important strategy to treat various dis-
eases. The goal is to increase efficacy and, through the avoidance of 
overlapping toxicity, improve the therapeutic index of treatment (Long et 
al., 2014). At the discovery stage, research often focuses on the identifi-
cation of synergistic target effects using in vitro systems (Sun et al., 
2013; Roemer and Boone, 2013; Lehár et al., 2009). Large scale combi-
nation screens testing multiple pairwise combinations of drugs across 
different concentration ranges and cell lines are being performed with 
increasing frequency (Mathews Griner et al., 2014; Held et al., 2013; He 
et al., 2015). Typically, the dose-response data generated during these 
experiments are then analysed in terms of synergistic or antagonistic 
effects. Free software were developed in the past but these are limited in 
terms of data handling and available options, particularly given high 
throughput screens (HTS) requirements (http://www.combosyn.com/; 
Dressler et al., 1999; Prichard and Shipman, 1990). Two recent commer-
cial software packages offer advanced features such as automated anal-
yses, choice from a variety of models, quality curve-fitting, variety of 
graphical displays and metrics quantification (Chalice 
http://cwr.horizondiscovery.com; Genedata https://www.genedata.com). 
There is a lack of free, advanced, scalable, software for the analysis of 
drug combinations. As part of the growing effort in the search of effec-
tive combinations, we present here Combenefit (“Combinations Bene-
fit”), a new software tool that enables the visualisation, analysis and 
quantification of drug combination effects, in terms of synergy and/or 
antagonism, for single combination experiments but also HTS as per 
commercial packages (Table 1). 
Associate Editor: Dr. Jonathan Wren
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2 General overview 
Table 1. Features of available software for drugs combinations analyses. 
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  Available Free Commerc. Commerc. Free Free 
Source code Yes No No No 
Spread-
sheet  
  Replicates Yes Yes Yes No Yes 
  Fitting 
(Hill model) 
3 params  3 params 
3 params + 
baseline 
2 params 
(no max) 
No 
Synergy   mod-
els 
L,B,H, 
(+planned) 
L,B,H, and 
2 others 
L,B,H, L based B 
Scores/metrics Several Several Several No No 
Graphics DR,M,C,S,
SM 
DR,M,C,I DR,M,C,I DR,I,F C,S 
Data input File File File Manual Manual 
HTS suitable Yes Yes Yes No No 
L: Loewe, B: Bliss, H: HSA, DR: Dose-response curve, M: Matrix view, C: con-
tours, S: surfaces, I: Isobolograms, SM: synergy mapped to dose-response surfaces, 
F: Fa related curves, see (Chou, 2010). Note: we have not included CombiTool 
(Dressler et al., 1999) because it does not appear to be available anymore. 
Combenefit implements a surface approach, where in vitro experimental 
data is compared to mathematical models of dose-responses for non-
synergistic combinations (also termed additive or independent combina-
tions; Greco W.R., Bravo G., 1995). The three classical models, namely 
the Loewe (Loewe and Muchnick, 1926; Loewe, 1953), the Bliss (Bliss, 
1939; Webb, 1963), and the Highest Single Agent (HSA; Tan et al., 
2012; Mathews Griner et al., 2014) models have been incorporated.  
These models have been used extensively in the literature, with different 
fields having their preference and sometimes alternative names for these 
same models (Greco W.R., Bravo G., 1995; Odds, 2003). It is important 
to use these models in a consistent way and to provide results in the 
context of the model used. Additionally, our own group is currently 
developing a new general model which, together with any other future 
feature, will be incorporated into Combenefit. 
The approach implemented in Combenefit can be summarized as follows 
(Figure 1a). The experimental dose-response surface that delineates 
combination effects in concentration space, is first read by the software 
as a matrix of % of the control value across concentrations. Single agent 
effects are extracted from this data and fitted with a dose response curve. 
Based on the two single agent dose response curves, a model-based 
combination dose-response surface is derived. This surface provides a 
“reference” dose-response surface for a non-synergistic (addi-
tive/independent) combination, whose characteristics are determined by 
the selected model (Loewe, Bliss etc.). The experimental combination 
dose response surface is then compared to the model-generated one, 
resulting in a synergy distribution in concentration space. This synergy 
distribution can be further summarized via various metrics as described 
below. 
3 Using Combenefit 
The software is available as a standalone application for Windows or as a 
Matlab package. The standalone application can be installed automatical-
ly and is then directly accessed through its own icon. The Matlab pack-
age needs to be saved in a dedicated folder which is then accessed via 
Matlab by calling the Combenefit routine contained in the package. La-
boratory scientists can quickly and easily analyse their data using either 
version. Bioinformaticians can use the code provided in the Matlab 
package to facilitate their own projects involving drugs combinations. 
3.1 Typical analysis 
A typical analysis is performed as follows. Upon completion of experi-
ments, the results of a specific combination (including replicates if avail-
able) are saved in .xls files (the data is ordered with the first drug in 
columns and the second in rows; a template is provided). Once Comben-
efit is launched, the project folder containing all experimental .xls files is 
selected (Figure 1b). Then, one or more reference models can be select-
ed. Other options and graphical outputs can be chosen as per require-
ments/preferences. The graphical outputs consist of: (i) the single agent 
dose response data and its fitting, (ii) the combination dose response (4 
different displays), (iii) the model-generated reference combination dose 
response i.e. the prediction of effect if the drugs are not synergistic (3 
different displays), and (iv) the resulting synergy distribution (3 different 
displays). Additionally, a fourth graphic mapping the synergy distribu-
tion onto the dose-response surface can also be displayed to facilitate 
interpretation. All figures, as well as corresponding data, fitting parame-
ters and synergy metrics (see below) can be saved in the project folder. 
Figures are saved as high quality .png or .pdf files which can be directly 
used in publications. A user’s guide with step-by-step guidance for in-
stalling and running the software is available online.  
 
 
Fig. 1 Analysis and visualisation of drug combinations with Combenefit. (a) 
Illustration of analysis principle. (b) Illustration of automated processing. 
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3.2 Metrics and batch analysis 
The analyses described above result in a synergy distribution for the 
combination being processed. To facilitate comparison across experi-
ments, or for HTS applications, it is useful to summarize the resulting 
synergy and/or antagonism distribution using one or more metrics. 
Combenefit provides a set of metrics (or scores) which captures infor-
mation about the synergy distribution. These include metrics such as the 
maximum synergy, the integrated and the weighted integrated synergy, 
and concentration value at which synergy is most dense (for a full list of 
metrics and their formulation, please see the supplementary material).  
During HTS, large volumes of combinations and cell lines are investi-
gated using automated technology. Combenefit can be used to analyse 
the large amount of data derived with these screens. Using Combenefit, 
the user selects the folder containing all experiments (each in an individ-
ual sub-folder) and then selects the “Batch Analysis” option. Upon run-
ning the analysis, Combenefit will batch process in a sequential way all 
the folders. The results of the analysis are summarized in a table contain-
ing all the experiments in rows and the metrics in columns. Typically, 
the highest hits are then visually inspected using Combenefit’s graphical 
outputs to improve understanding of the data and prioritize drug combi-
nations. Combenefit has been recently used to generate the AstraZeneca 
dataset (~11500 combinations) provided for the current AstraZeneca-
Sanger Drug Combination Prediction DREAM challenge 
(http://dreamchallenges.org/).  
 
In summary, we have described the overall implementation and function-
ing of Combenefit, new software which offers advanced graphical capa-
bilities and allows for model-based quantification of drug combinations 
in single and high-throughput settings.  We hope that this new tool will 
continue to improve and will help many scientists in a variety of fields 
involving combination data analyses. 
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